A new diabetes drug that sits in the same class as Byetta has been found to be effective in cutting blood sugar levels and lowering weight, following a year long study involving people with type 2 diabetes .
The drug, liraglutide, is based on a hormone called GLP-1 that stimulates insulin secretion. Related drugs called DPP-4 inhibitors are also concerned with the hormone, although in a slightly different way. DPP-4 inhibitors include Galvus and Januvia .
Byetta has been in the news lately for having a rare side effect called pancreatitis. It is not yet clear whether liraglutide will cause a similar response amongst an extreme minority of patients.
The study, conducted by the Baylor College of Medicine, compared liraglutide to Amaryl, another diabetic drug .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…